Key Takeaways

Hidradenitis suppurativa is a painful chronic skin condition associated with overweight and obesity.

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis suppurativa disease activity and pain 6 months later.

Researchers suggested that hidradenitis suppurativa patients without obesity may benefit from GLP-1 drugs as well.

Patients with hidradenitis suppurativa who started taking GLP-1 receptor agonists experienced reductions in a long list of disease measures, a small retrospective study found.

Six months after treatment initiation, patients were significantly more likely to experience a 1-point or greater reduction in Hidradenitis Suppurativa Physician's Global Assessment (HS-PGA) score, along with reductions

See Full Page